Dynamic Advisor Solutions LLC Decreases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Dynamic Advisor Solutions LLC lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 500 shares of the company’s stock after selling 174 shares during the period. Dynamic Advisor Solutions LLC’s holdings in IDEXX Laboratories were worth $210,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IDXX. Hurley Capital LLC purchased a new position in IDEXX Laboratories in the 4th quarter valued at $29,000. Rialto Wealth Management LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth $30,000. Colonial Trust Co SC raised its holdings in shares of IDEXX Laboratories by 84.8% during the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock worth $35,000 after acquiring an additional 39 shares during the period. Kestra Investment Management LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth $38,000. Finally, Itau Unibanco Holding S.A. raised its holdings in shares of IDEXX Laboratories by 540.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company’s stock worth $40,000 after acquiring an additional 81 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on IDXX. Stifel Nicolaus lifted their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a “hold” rating in a report on Monday, May 19th. Leerink Partners lifted their price target on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, June 11th. Morgan Stanley lifted their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a report on Monday, May 5th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $546.00.

IDEXX Laboratories Stock Up 0.8%

Shares of NASDAQ:IDXX opened at $523.92 on Friday. The business has a 50-day moving average price of $486.81 and a 200 day moving average price of $447.64. The company has a current ratio of 1.16, a quick ratio of 0.81 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $42.13 billion, a price-to-earnings ratio of 48.42, a PEG ratio of 3.80 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $530.73.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The company’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period last year, the company earned $2.71 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,046 shares of IDEXX Laboratories stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $513.74, for a total value of $537,372.04. Following the completion of the transaction, the director now directly owns 262 shares of the company’s stock, valued at $134,599.88. The trade was a 79.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.